Table 1 Clinicopathological characteristics of 10 patients.

From: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility

Patient	Age at surgery	Menopause	Gravidity/parity	Primary or recurrent	cStage	cTNM	Histological type^a	ER^b	PgR^b	HER2	Subtype classification	Ki67	Neoadjuvant
P1	76	Post	g3p2	P	I	cT1cN0M0	IDC	5 + 3	5 + 3	0	ER + /HER2−	19%	None
P3	53	Post	g0p0	P	I	cT1cN0M0	IDC	5 + 3	4 + 2	1+	ER + /HER2−	7%	None
P4	65	Post	g1p1	P	IIA	cT2N0M0	IDC	0 + 0	0 + 0	0	TNBC	85%	None
P5	79	Post	g2p0	R	I	cT1cN0M0	IDC	0 + 0	0 + 0	1+	TNBC	85%	None
P7	78	Post	g3p3	P	IIA	cT1cN1M0	IDC	0 + 0	0 + 0	0	TNBC	65%	None
P8	69	Post	g2p2	P	I	cT1micN0M0	Microinvasive	2 + 2	1 + 2	2+	ER + /HER2−	65%	None
P9	37	Pre	g0p0	P	IIA	cT2N0M0	IDC	5 + 2	5 + 2	1+	ER + /HER2−	15%	None
P11	39	Pre	g0p0	P	IIB	cT2N1M0	IDC	5 + 2	4 + 3	1+	ER + /HER2−	30%	None
P12	68	Post	g2p2	P	I	cT1cN0M0	IDC	5 + 3	5 + 3	0	ER + /HER2−	8%	None
P13	62	Post	g2p2	P	IIB	cT2N1M0	IDC	5 + 3	5 + 3	1+	ER + /HER2−	8%	None
P14	52	Pre	g2p1	P	I	cT1cN0M0	IDC	5 + 2	5 + 2	2 + ,DISH(−)	ER + /HER2−	5%	None
P15	40	Pre	g2p2	P	IIA	cT2N0M0	Mixed	5 + 2	5 + 3	1+	ER + /HER2−	7%	None
P17	55	Post	g0p0	P	IIA	cT2N0M0	Metaplastic	0 + 0	0 + 0	0	TNBC	30%	None
P18	53	Post	g0p0	P	I	cT1cN0M0	IDC	4 + 3	3 + 3	1+	ER + /HER2−	8%	None
P19	49	Pre	g1p1	P	I	cT1cN0M0	IDC	5 + 2	5 + 2	0	ER + /HER2−	15%	None
P20	54	Post	g3p2	P	IIIA	cT1cN2aM0	Metaplastic	0 + 0	0 + 0	0	TNBC	65%	None
P21	62	Post	g2p2	P	IIA	cT2N0M0	IDC	5 + 3	5 + 3	0	ER + /HER2−	10%	None
P22	51	Pre	g3p1	P	IIA	cT2N0M0	IDC	5 + 2	5 + 3	0	ER + /HER2−	45%	None
P23	69	Post	g2p1	P	I	cT1cN0M0	IDC	5 + 3	4 + 3	2+	ER + /HER2−	25%	None
P24R	54	Post	g3p2	P	I	cT1cN0M0	IDC	5 + 3	2 + 2	2 + ,DISH(−)	ER + /HER2−	3%	None
P24L	54	Post	g3p2	P	IIB	cT3N0M0	Mixed	4 + 3	0 + 0	0	ER + /HER2−	25%	None
P26	52	Pre	g1p1	P	I	cT1cN0M0	IDC	5 + 3	5 + 3	1+	ER + /HER2−	25%	None
P27	68	Post	g4p2	P	I	cT1cN0M0	IDC	5 + 3	1 + 2	0	ER + /HER2−	20%	None
P28	44	Pre	g2p2	P	IIA	cT2N0M0	IDC	3 + 1	0 + 0	0	ER + /HER2−	85%	None
P29	47	Pre	g0p0	P		TisN1M0	IDC	5 + 3	5 + 3	2 + ,DISH(−)	ER + /HER2−	25%	None
P30	70	Post	g2p2	P	IIIA	cT2N2bM0	IDC	5 + 3	4 + 2	1+	ER + /HER2−	10%	None
P31	78	Post	g2p2	P	IIIA	cT3N1M0	IDC	5 + 3	3 + 2	1+	ER + /HER2−	7%	Yes^c
P32	68	Post	g3p3	P	IIA	cT2N0M0	IDC	5 + 3	4 + 3	0	ER + /HER2−	3%	None
P33	35	Pre	g1p1	P	I	cT1cN0M0	Mucinous	5 + 2	2 + 3	1+	ER + /HER2−	25%	None
P34	82	Post	g3p3	P	I	cT1cN0M0	IDC	5 + 2	3 + 1	0	ER + /HER2−	20%	None
P35	45	Pre	g2p1	P	I	cT1cN0M0	IDC	5 + 3	5 + 3	0	ER + /HER2−	3%	None
P36	54	Post	NA	P	IIA	cT2N0M0	IDC	5 + 3	3 + 3	1+	ER + /HER2−	40%	None
P37	91	Post	NA	P	IIA	cT2N0M0	Mucinous	5 + 3	4 + 3	1+	ER + /HER2−	8%	None
P38	63	Post	g2p2	P	I	cT1cN0M0	IDC	5 + 3	5 + 3	1+	ER + /HER2−	8%	None
P39	66	Post	g3p2	P	IIA	cT2N0M0	ILC	5 + 3	5 + 3	1+	ER + /HER2−	7%	None
P41	48	Pre	g1p1	P	I	cT1bN0M0	IDC	0 + 0	0 + 0	0	TNBC	85%	None
P44	60	Post	g2p2	P	IIA	cT2N0M0	IDC	0 + 0	0 + 0	1+	TNBC	80%	None
P49	73	Post	g0p0	P	IIA	cT2N0M0	IDC	5 + 3	5 + 3	2 + ,DISH(−)	ER + /HER2−	15%	None
P50	61	Post	g1p1	P	I	cT1cN0M0	IDC	5 + 3	0 + 0	1+	ER + /HER2−	10%	None
P54	67	Post	g0p0	P	I	cT1bN0M0	ILC	5 + 3	2 + 2	1+	ER + /HER2−	5%	None
P64	51	Post	g3p1	P	IIA	cT2N0M0	Mucinous	5 + 3	5 + 3	1+	ER + /HER2−	20%	None
P65	71	Post	g3p2	P	IIA	cT2N0M0	DCIS	1 + 2	1 + 1	2+	ER + /HER2−	15%	None

^aIDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ.
^bIHC score based on Allred scoring system: Proportion score (ranging 0–5) plus intensity score (ranging 0–3) Proportion score (%Positive cells): 0 (0%), 1 (<1%), 2 (1–10%), 3 (11–33%), 4 (34–66%), 5 (≥67%) Intensity score: 0 (None), 1 (Weak), 2 (Intermediate), 3 (Strong).
^c4 cycles of CEF (Cyclophosphamide, Epirubicin and 5FU) and 3wDOC (triweekly docetaxel).

Back to article page

Table 1 Clinicopathological characteristics of 10 patients.

Search

Quick links